Alpuente A, Gallardo VJ, Caronna E, Torres-Ferrus M, Pozo-Rosich P In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study. J Headache Pain. 2021 Dec 13;22(1):151. doi: 10.1186/s10194-021-01366-9.
Edvinsson L, Haanes KA, Warfvinge K, Krause DN CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol. 2018 Jun;14(6):338-350. doi: 10.1038/s41582-018-0003-1. Review.
Iannone LF, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score. CNS Drugs. 2022 Feb;36(2):191-202. doi: 10.1007/s40263-021-00893-y. Epub 2022 Feb 11.
Iannone LF, Fattori D, Benemei S, Chiarugi A, Geppetti P, De Cesaris F Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine. Eur J Neurol. 2022 May;29(5):1505-1513. doi: 10.1111/ene.15260. Epub 2022 Feb 13.
Lambru G, Hill B, Murphy M, Tylova I, Andreou AP A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain. 2020 Jun 1;21(1):61. doi: 10.1186/s10194-020-01127-0.
Schoenen J, Timmermans G, Nonis R, Manise M, Fumal A, Gérard P Erenumab for Migraine Prevention in a 1-Year Compassionate Use Program: Efficacy, Tolerability, and Differences Between Clinical Phenotypes. Front Neurol. 2021 Dec 10;12:805334. doi: 10.3389/fneur.2021.805334. eCollection 2021.
Stewart WF, Lipton RB, Kolodner KB, Sawyer J, Lee C, Liberman JN Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain. 2000 Oct;88(1):41-52. doi: 10.1016/S0304-3959(00)00305-5.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
